We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Brain Toxicity Map May Help Protect Cognition for Cancer Patients

By HospiMedica International staff writers
Posted on 04 Apr 2013
New research is giving radiation oncologists who treat brain tumors a better determination of how to maintain the brain’s functions while still killing cancer.

Ann M. More...
Peiffer, PhD, assistant professor of radiation oncology at Wake Forest Baptist Medical Center (Winston-Salem, NC, USA), and colleagues looked at how radiation treatment to different brain region impacts function to help protect cognition for patients during and after radiation therapy and beyond.

Treating cancerous organs with radiation is devised to give enough of a dose to be toxic to the cancer tumor with minimal impact to the neighboring tissue and circumvent normal tissue death. For treatment of organs such as the lung, liver, or kidney, clinicians know precisely how much radiation to give before organ function is affected.

However, the same is not true for brain tissue, so the researchers worked to develop a “toxicity map” of the brain to preserve function. Dr. Peiffer noted that this is the first attempt to relate treatment dose to brain function, as opposed to brain tissue death. While avoiding healthy tissue death is important, it does not automatically help prevent the cognitive and functional problems associated with cancer treatments. “The issue is the toxicity to the brain and its function, which is cognition or how you think, and these functions are affected at a much lower dose of radiation than what causes tissue death,” Dr. Peiffer said.

The toxicity map was generated by exploiting the data from larger clinical trials held at Wake Forest Baptist. In one of those trials, 57 brain cancer survivors returned six months or more after their radiation treatment to determine whether Donepezil, a drug normally used to improve mental function for those with early Alzheimer’s disease, was effective at improving their cognition. Participants completed cognitive testing upon enrollment, and their scores provided the performance data for the toxicity map. The researchers then went back into the medical records to match participants to their individual radiation dose levels and MRI scans captured before treatment, according to Dr. Peiffer.

“By matching cognitive performance to these measurements, we determined which area of the brain and what dose influenced performance on the cognitive tasks,” Dr. Peiffer said. “This gave us a preliminary look at what areas are important to consider for protecting cognition during our planning for radiation treatment.”

Dr. Peiffer reported that by looking at the irradiation dose received by specific brain regions important to different cognitive functions, tolerance levels related to function could be ascertained. The exposed amount of these vital brain areas were then related to outcomes of specific tests used to assess cognition or the ability of the patients to think and perform tasks, such as remembering a grocery list or what a drawing looked like, she noted. “As technology advances and we are able to spare increasing amounts of normal tissue and important functional structures during treatment, it is important to understand and be able to predict the threshold that we need to maintain to prevent treatment toxicities in function,” Dr. Peiffer said.

New developments in cancer treatment have increased survivorship rates and the length of time individuals are able to live following treatment, according to Dr. Peiffer, and quality of life becomes a very significant matter for these patients. More research, however, is necessary to validate these data, she said.

Related Links:

Wake Forest Baptist Medical Center



Gold Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Ureteral Dilatation Balloon
Dornier Equinox
Ultrasound Needle Guidance System
SonoSite L25
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: The AI-based approach identifies lipid regions matched well with histopathology results (Photo courtesy of Hyeong Soo Nam/KAIST)

AI-Based OCT Image Analysis Identifies High-Risk Plaques in Coronary Arteries

Lipid-rich plaques inside coronary arteries are strongly associated with heart attacks and other major cardiac events. While optical coherence tomography (OCT) provides detailed images of vessel structure... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.